Corvus’s new presentation at the ESMO congress 2025

Image Credit: The Manila Times

Announcement 

Corvus Pharmaceuticals Inc., a leading clinical-level biopharmaceutical company, will be showcasing the interim data from the comprehensive phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer (RCC) patients today in the oral presentation format at the European Society for Medical Oncology (ESMO) congress 2025. The ESMO is held in Berlin, Germany, on October 17-21, 2025. The presenter of the data is the MD, PhD, director of genitourinary cancer research at Tennessee Oncology and member of the kidney cancer research consortium (KCRC), Katy Beckermann, in the same group organising the trial in partnership with Corvus.

The MD, president, co-founder and chief executive officer of Corvus, Richard A. Miller, said, “We are empowered with these results discovering ciforadenant in combination with nivolumab and ipilimumab as a capable front-line treatment for renal cell carcinoma. Though after enrolling patients having extreme disease in comparison to historical trials, the triplet merger elaborated the activity that weighs in favour of the historical results with the doublet one. These data contribute to our point of view of the stoppage of adenosine aligning with ciforadenant that might deliver a valuable benefit for RCC patients. We are thankful to be partnered with the Kidney Cancer Research Consortium. Further, we are looking forward to achieving consistency to lead the 19 patients who are on therapy to understand the depth of the ability of this idea.”

Open-label phase 1b/2 clinical trial details

The open-label phase 1b/2 clinical trial is examining ciforadenant. It’s a corvus’s adenosine A2a receptor inhibitor considered as a capable first-line therapy for metastatic RCC in merger with nivolumab and ipilimumab. The trial included a total of 50 patients, further divided into 8 for the phase 1b portion, and the remaining 42 for the phase 2 portion, with recurrent stage 4 clear cell RCC (not yet received any prior systemic therapy or newly diagnosed. The primary conclusion for the phase 1b portion is anti-tumour, safety and tolerability response. Including the percentage of patients who gain a deep response demonstrated as a complete response or partial response of specific >50% tumour volume reduction.

 The historical data from the kidney cancer research consortium have highlighted that the ocean deep response aligns with the prolonged progression-free survival as well as its occurrence in an estimated 32% of patients receiving nivolumab and ipilimumab. The secondary part of the conclusion (focus) for the phase 2 portion consists of progression-free survival (PFS), treatment-related adverse events and objective response rate (ORR).